That would be a mistake.
MSBs strategy is paying off by using this as their lead product to market. They have breached a significant boundary and now made it easier to overcome historical prejudice for this technology. Obviously they need to front up with the goods on the other products, but this is more than just a win for this product, its a win for this technology and more importantly for the patients and their families.
That aside and obviously subject to FDA final approvals, there are a number products in the pipeline and one in particular that has incredible upside. Further afield, inflammation is a general underlying health issue for many conditions, so the question is how can this technology be further modified to treat patients who suffer those ailments.
Bottom line is the downside vs the upside potential now is significantly greater than before the panic sell a couple of days ago!
Ryoncil: ODAC/FDA Meeting Discussion, page-1873
-
- There are more pages in this discussion • 174 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |